Supplementary Table

This is the cluster proportion of PBMCs in controls and stroke patients measured by scRNA-sequencing (supplementary table 1) and flow cytometry (supplementary table 2). Data is shown in a relative percentage and 95% confidential intervals. P values are measured between stroke patients and controls.

Supplementary Table 1. Cluster proportion of PBMCs in controls and stroke patients analyzed by scRNA-sequencing.

Cell type	Controls	Stroke patients	p value
CD14+ monocytes	25.0% [18.7-21.3]	24.0% [12.5-35.5]	0.624
B cells	13.6% [10.1-17.0]	14.2% [1.3-27.4]	0.086
CD4+ T cells	11.8% [7.1-16.5]	14.3% [7.4-21.2]	0.806
CD8+ T cells	12.7% [5.8-19.5]	12.7% [5.8-19.6]	0.935
CD16+ monocytes	10.3% [5.1-15.4]	8.1% [5.0-11.2]	0.744
NK cells	6.2% [5.0-7.4]	11.6% [7.7-15.5]	0.022
CD14+ monocytes subtype	9.4% [3.2-15.6]	3.8% [1.7-5.9]	0.018
Megakaryocytes	6.4% [3.9-8.8]	4.8% [2.4-7.2]	0.165
Classical dendritic cells	3.6% [2.2-5.0]	2.8% [1.8-3.8]	0.514
Megakaryocytes subtype	0.1% [0.0-0.3]	3.0% [0.0-0.8]	0.209
Plasmacytoid dendritic cells	1.0% [0.6-1.4]	0.8% [0.3-1.2]	0.369

Supplementary Table 2. Cluster proportion of PBMCs in controls and stroke patients analyzed by flow cytometry.

Cell type	Controls	Stroke patients	p value
T cells (total)	43.9% [36.4-51.4]	35.5% [25.4-45.6]	0.205
CD4+ T cells	33.1% [25.3-40.1]	25.2% [16.3-34.0]	0.153
CD8+ T cells	8.8% [6.0-11.6]	2.2% [0.0-4.3]	0.004
CD3+/CD56+ cells	3.5% [1.1-5.9]	3.5% [1.3-5.7]	0.967
NK cells	8.3% [5.9-10.7]	15.0% [9.2-20.8]	0.025
B cells	12.2% [9.8-14.6]	14.6% [1.8-27.3]	0.142
Monocytes (total)	25.3% [20.5-30.0]	19.9% [15.8-24.0]	0.153
Classical monocytes (CD14++/CD16-)	22.7% [18.2-27.2]	17.2% [13.5-20.8]	0.102
Intermediate monocytes (CD14++/CD16+)	1.0% [0.5-1.5]	1.0% [0.4-1.6]	1.000
Nonclassical monocytes (CD14+/CD16++)	0.4% [0.04-0.08]	0.7% [0.2-1.2]	0.497